JPMorgan Chase & Co. Issues Pessimistic Forecast for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Dyne Therapeutics (NASDAQ:DYN) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $10.00 to $9.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential downside of 3.54% from the company’s current price.

Other research analysts also recently issued reports about the company. Oppenheimer began coverage on Dyne Therapeutics in a research note on Monday, June 2nd. They set an “outperform” rating and a $34.00 price target on the stock. Evercore ISI reaffirmed an “outperform” rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Jones Trading started coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They set a “buy” rating and a $30.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, June 17th. Finally, Guggenheim reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.63.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $9.33 on Tuesday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.60 and a beta of 1.08. The business’s 50-day moving average is $11.28 and its 200-day moving average is $12.50. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). Analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, CEO John Cox acquired 100,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were bought at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the transaction, the chief executive officer owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.14% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $2,340,000. Schroder Investment Management Group grew its stake in shares of Dyne Therapeutics by 63.3% during the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company’s stock valued at $3,477,000 after buying an additional 56,961 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Dyne Therapeutics by 4.2% during the first quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock valued at $1,398,000 after buying an additional 5,383 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Dyne Therapeutics by 54.5% during the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company’s stock valued at $913,000 after buying an additional 13,677 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of Dyne Therapeutics by 3.3% during the fourth quarter. Swiss National Bank now owns 108,600 shares of the company’s stock valued at $2,559,000 after buying an additional 3,500 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.